XNASERNA
Market cap12mUSD
Dec 27, Last price
0.25USD
1D
-10.63%
1Q
-78.00%
Name
Eterna Therapeutics Inc
Chart & Performance
P/E
—
P/S
191.14
EPS
—
Div Yield, %
0.12%
Shrs. gr., 5y
139.67%
Rev. gr., 5y
-68.89%
Revenues
68k
Net income
-22m
L-11.84%
CFO
-20m
L-2.71%
Earnings
Mar 12, 2025
Profile
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 68 | ||||||||
Cost of revenue | 20,743 | 27,724 | 27,888 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (20,675) | (27,724) | (27,888) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (3) | 45 | 5 | ||||||
Tax Rate | |||||||||
NOPAT | (20,672) | (27,769) | (27,893) | ||||||
Net income | (21,668) -11.84% | (24,579) -79.90% | (122,306) -1,127.26% | ||||||
Dividends | (16) | (16) | (8) | ||||||
Dividend yield | 0.17% | 0.16% | |||||||
Proceeds from repurchase of equity | 320 | 19,706 | 62,535 | ||||||
BB yield | -3.35% | -200.59% | |||||||
| Debt | |||||||||
Debt current | 4,432 | 2,045 | 426 | ||||||
Long-term debt | 74,697 | 3,275 | 5,020 | ||||||
Deferred revenue | 392 | ||||||||
Other long-term liabilities | 307 | 424 | 19,953 | ||||||
Net debt | 67,459 | (6,185) | (12,539) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (20,408) | (20,976) | (23,488) | ||||||
CAPEX | (19) | (297) | (154) | ||||||
Cash from investing activities | (19) | (47) | (22,742) | ||||||
Cash from financing activities | 16,556 | 19,579 | 61,585 | ||||||
FCF | (52,680) | (25,798) | (29,037) | ||||||
| Balance | |||||||||
Cash | 7,575 | 11,446 | 16,985 | ||||||
Long term investments | 4,095 | 59 | 1,000 | ||||||
Excess cash | 11,667 | 11,505 | 17,985 | ||||||
Stockholders' equity | (186,953) | (165,210) | (159,442) | ||||||
Invested Capital | 233,944 | 181,880 | 188,620 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 5,314 | 3,051 | 2,165 | ||||||
Price | 1.80 -44.25% | 3.22 | |||||||
Market cap | 9,539 -2.91% | 9,824 | |||||||
EV | 76,999 | 3,700 | |||||||
EBITDA | (19,552) | (27,227) | (27,429) | ||||||
EV/EBITDA | |||||||||
Interest | 614 | 30 | 74 | ||||||
Interest/NOPBT | |||||||||